Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.63 Million | -894.39 Million | -9.93 Million | -8.56 Million | -5.95 Million | -3.73 Million |
| Net Income | 279.83 Thousand | -932.42 Million | -12.76 Million | -9.15 Million | -8 Million | -4.17 Million |
| Depreciation & Amortization | - | 15.97 Million | 2.71 Million | 927.7 Thousand | 1.04 Million | 1.2 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 217.08 Thousand | -1.97 Million | 113.78 Thousand | -335.49 Thousand | 999.69 Thousand | -78.75 Thousand |
| Other non-cash items | -5.13 Million | 24.03 Million | 0.60 | 2.19 Million | 1.22 | -676.31 Thousand |
| Investing Cash Flow | 607.08 Thousand | -21.01 Million | -1.05 Million | 3691.16 | - | 7165.78 |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | 3691.16 | - | 7165.78 |
| Investment purchases | - | -21.01 Million | -105.4 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 607.08 Thousand | -210.13 Thousand | 104.35 Million | - | - | - |
| Financing Cash Flow | 4.49 Million | 855.94 Million | 4.03 Million | 14.88 Million | 10.77 Million | 508.61 Thousand |
| Debt repayment | -10.63 Thousand | -150.21 Thousand | -5661.00 | -5661.00 | -5661.00 | -508.61 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 4.5 Million | 870.96 Million | 4.03 Million | 14.88 Million | 9.94 Million | - |
| Other Financing Activities | 0.08 | -14.87 Million | 4033.84 | 14.88 Thousand | 831.42 Thousand | 508.61 Thousand |
| Accounts receivables | -16.07 Thousand | -98.54 Thousand | -33.56 Thousand | 45.47 Thousand | -157.29 Thousand | -17.22 Thousand |
| Accounts payables | - | 78.82 Thousand | 149.86 Thousand | -380.96 Thousand | 1.15 Million | -61.53 Thousand |
| Inventory | - | - | -0.60 | - | -0.55 | - |
| Other working capital | 233.15 Thousand | -1.95 Million | -2504.40 | -0.17 | -0.45 | -61.53 Thousand |
| Cash at beginning of period | 5.03 Million | 563.04 Million | 12.33 Million | 6.99 Million | 2.18 Million | 5.4 Million |
| Cash at end of period | 5.5 Million | 503.57 Million | 6.43 Million | 13.32 Million | 6.99 Million | 2.18 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | 1.05 Million | - | - | 0.79 |
| Net cash flow / Change in cash | 467.23 Thousand | -59.46 Million | -5.89 Million | 6.32 Million | 4.81 Million | -3.21 Million |
| Free Cash Flow | -4.63 Million | -894.39 Million | -9.93 Million | -8.56 Million | -5.95 Million | -3.73 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.68 Million | -1.34 Million | 2.07 Million | 279.83 Thousand | 1.03 Million | -1.79 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -308 Thousand | -154 Thousand | -247.95 Thousand | 217.08 Thousand | -247.95 Thousand | 356.5 Thousand |
| Other non-cash items | -40 Thousand | -20 Thousand | -3.28 Million | -5.13 Million | -2.24 Million | -278.5 Thousand |
| Investing Cash Flow | -474 Thousand | -237 Thousand | 81.36 | 607.08 Thousand | 0.04 | 607 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | 81.36 | 607.08 Thousand | - | 607 Thousand |
| Investment purchases | -1.5 Million | - | - | - | - | - |
| Sales/Maturities of investments | 1.02 Million | - | - | - | - | - |
| Other Investing Activities | - | -237 Thousand | - | 607.08 Thousand | 0.04 | - |
| Financing Cash Flow | -2500.00 | -2500.00 | 4.49 Million | 4.49 Million | 2247.58 | 500.00 |
| Debt repayment | -5000.00 | - | -10.63 Thousand | -10.63 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 4.5 Million | 4.5 Million | - | 1000.00 |
| Other Financing Activities | -2500.00 | -2500.00 | -10.63 Thousand | -1.00 | 2247.58 | -500.00 |
| Accounts receivables | 49 Thousand | 49 Thousand | -15.53 Thousand | -16.07 Thousand | -15.53 Thousand | 7500.00 |
| Accounts payables | - | - | - | 233 Thousand | - | - |
| Inventory | - | - | - | -233 Thousand | - | - |
| Other working capital | -357 Thousand | -203 Thousand | -232.42 Thousand | 233.15 Thousand | -232.42 Thousand | 349 Thousand |
| Cash at beginning of period | 5.5 Million | - | 3.92 Million | 5.03 Million | 3.92 Million | - |
| Cash at end of period | 1.98 Million | -1.75 Million | 5.5 Million | 5.5 Million | 788.12 | 3.92 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | 203.00 | - | - |
| Net cash flow / Change in cash | -3.51 Million | -1.75 Million | - | 467.23 Thousand | -3.92 Million | 3.92 Million |
| Free Cash Flow | -3.03 Million | -1.51 Million | -1.45 Million | -4.63 Million | -1.45 Million | -858.5 Thousand |
OOA
MXF
MAV4
ODL
601996
TCOR